Novoclem Therapeutics’ lead drug candidate, a nitric oxide-releasing biopolymer, can eliminate nine of the most prevalent microorganisms responsible for severe lung infections in cystic fibrosis (CF) patients, the Morrisville, N.C., company reported. “Our mission is to arm patients with therapies that treat resistant bacteria and enable them to breathe…
News
A small proof-of-concept Phase 2 trial (NCT02722122) of alidornase alfa showed that the therapy improved lung function in patients with cystic fibrosis (CF), according to its developer Protalix BioTherapeutics. In addition to making breathing difficult, the thick mucus in CF patients’ airways makes ideal growth conditions for many…
Swiss-based Polyphor has secured financing for late-stage development of Murepavadin (POL7080), an antibiotic targeting a bacteria that often infects the airways of cystic fibrosis (CF) patients. A hallmark of the therapy is that it goes after antibiotic-resistant strains of Pseudomonas aeruginosa, which infects not just MS patients, but people with other…
A pancreatic enzyme replacement product that is not derived from pigs — Sollpura (liprotamase) — was as good at maintaining the height and weight of cystic fibrosis (CF) patients as a pig-derived product, according to a clinical trial. The information came from the extension period of Anthera’s Phase 3…
The naturally occurring molecule thymosin α1 (Tα1) reversed tissue defects in mice with cystic fibrosis (CF) and in human cells that contained a mutation associated with the disease, according to a study. The findings mean that Tα1 could be a promising treatment for CF patients carrying the F508del mutation in…
Enterprise Therapeutics has received a £95,000 grant from Britain’s Cystic Fibrosis Trust to develop innovative treatments for cystic fibrosis (CF). The money, equivalent to $118,000, will support the development of CF therapies based on Enterprise Therapeutics’ bronchosphere technology platform. Cystic fibrosis blocks airway passages. The condition stems from faulty airway-surface…
AbbVie is accepting applications for its 2017 AbbVie CF Scholarship program that helps to support outstanding young adults with cystic fibrosis (CF) as they pursue higher education. A total of 40 scholarships, each worth $3,000, are available for the current 2017–18 academic year. Awards based on established criteria that…
Spyryx Biosciences presented new data and updates on its cystic fibrosis (CF) treatment SPX-101 at two recent events: the European Cystic Fibrosis Society Basic Science Conference, which took place March 29-April 1 in Albufeira, Portugal, and the invitation-only Needham & Company’s 16th Annual Healthcare Conference, held April 4-5 in New…
The first patient has been dosed in a Phase 2 clinical trial evaluating RPL554 as a treatment for cystic fibrosis (CF), according to its maker, Verona Pharma. RPL554 is a first-in-class drug candidate designed to inhibit the enzymes phosphodiesterase 3 and 4 (PDE3/PDE4). It has been shown to have…
Dutch pharmaceutical company ProQR Therapeutics now has two key patents protecting its first-in-class ribonucleic acid (RNA)-based oligonucleotide QR-010 for the treatment of cystic fibrosis (CF) in the United States and Europe. The patents are valid until at least July 2033. The new U.S. patent, announced April 3, covers methods of targeting…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.